Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chimerix Inc (NQ: CMRX )

0.9137 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Chimerix Inc

< Previous 1 2 3 4 5 6 Next >
Chimerix (CMRX) Stock Plummets 60% After Q1 Earnings Disappointment
Chimerix (CMRX) stock is falling hard on Monday following the release of its earnings report for the first quarter of 2022. 
Via InvestorPlace
Mid-Morning Market Update: Markets Open Lower; Dow Drops 70 Points
U.S. stocks traded lower this morning, with the Nasdaq Composite adding more than 400 points on Friday. 
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Biopharma stocks remained largely unchanged in the week ending May 13, with the defensive nature of the sector coming to its aid. Stocks reacted to the broader market move and earnings news from... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Recap: Chimerix Q1 Earnings
Chimerix (NASDAQ:CMRX) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
Chimerix Confirms Ongoing Negotiations With BARDA On Smallpox Medicine Contract
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back and get ready for another busy week of trading as we start it off with the biggest pre-market stock movers for Monday! 
Via InvestorPlace
Chimerix's Earnings Outlook
Chimerix (NASDAQ:CMRX) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Chimerix will report... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Looking Into Chimerix's Return On Capital Employed
Benzinga Pro data, Chimerix (NASDAQ:CMRX) reported Q4 sales of $46.00 thousand. Earnings fell to a loss of $39.50 million, resulting in a 112.81% decrease from last quarter.... 
Via Benzinga
Chimerix: Q4 Earnings Insights
Chimerix (NASDAQ:CMRX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Chimerix's CMX521 Antiviral Program Shows Potential Against COVID-19 In Preclinical Studies
Chimerix Inc's (NASDAQ: CMRX) preclinical data from its CMX521 program will be featured at the International Conference on Antiviral Research (ICAR) in March. In vivo,... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Barclays lifted the price target on FactSet Research Systems Inc. (NYSE: 
Via Benzinga
52 Biggest Movers From Yesterday
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland... 
Via Benzinga
Exposures Product Safety
35 Stocks Moving In Tuesday's Mid-Day Session
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares jumped 105.9% to $4.53. The FDA approved expanded labeling for Cumberland Pharmaceuticals’ Caldolor, an... 
Via Benzinga
Exposures Product Safety
20 Stocks Moving In Tuesday's Pre-Market Session
Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) rose 117.3% to $4.78 in pre-market trading after the company announced the FDA approved expanded labeling for Caldolor to... 
Via Benzinga
Exposures Product Safety
Chimerix (CMRX) Q3 2021 Earnings Call Transcript
CMRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at... 
Via Benzinga
Exposures Product Safety
Chimerix Shares Brain Cancer Trial Data
Chimerix Inc (NASDAQ: CMRX) has reported topline data from its 50-patient efficacy analysis of ONC201 for recurrent H3 K27M-mutant glioma (a most common type of... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Evaxion Biotech (NASDAQ:EVAX) shares increased by 244.61% to $22.4 during Thursday's pre-market session. The company's market cap stands at $430.0 million... 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers OpGen (NASDAQ:OPGN) shares moved upwards by 30.07% to $3.59 during Monday's pre-market session. The market value of their outstanding shares is at $137.3... 
Via Benzinga
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Xeris Pharmaceuticals (NASDAQ:XERS 
Via Benzinga
Return on Capital Employed Insights for Chimerix
After pulling data from Benzinga Pro it seems like during Q2, Chimerix's (NASDAQ:CMRX) reported sales totaled $391.00 thousand. Despite a 81.72% in earnings, the company posted a... 
Via Benzinga
Chimerix (CMRX) Q2 2021 Earnings Call Transcript
CMRX earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.